Physician profile
Vandankumar Patel
NPI 1043743255
$501.32
in general payments reported to CMS, 2019-2025
16 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.10 · 2023: $46.25 · 2024: $114 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102.37 | 2023-2025 | |
| Mylan Specialty L.P. | $54.63 | 2023-2024 | Yupelri |
| Ethicon INC. | $39.71 | 2025 | Monarch Platform |
| Pulmonx Corporation | $37.20 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Travere Therapeutics, INC. | $36.09 | 2024-2025 | |
| Insmed, INC. | $36.01 | 2025 | Arikayce |
| Amgen INC. | $29.10 | 2025 | Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $24.33 | 2024 | Entyvio |
| Viatris Specialty LLC | $23.37 | 2025 | Yupelri |
| Calliditas Therapeutics US INC. | $21.54 | 2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $19.10 | 2022 | |
| Merck Sharp & Dohme LLC | $16.95 | 2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Novartis Pharmaceuticals Corporation | $16.13 | 2023 | |
| Lilly USA, LLC | $15.31 | 2025 | Omvoh |
| Astrazeneca Pharmaceuticals LP | $15.16 | 2025 | Fasenra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2025 | Jascayd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandankumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.